Holen Sie sich die Stockscreener-App
317.20
0.33%
1.04
Schlusskurs vom Vortag:
$316.16
Offen:
$315.81
24-Stunden-Volumen:
672.78K
Relative Volume:
1.37
Marktkapitalisierung:
$12.48B
Einnahmen:
$1.45B
Nettoeinkommen (Verlust:
$171.05M
KGV:
72.99
EPS:
4.3459
Netto-Cashflow:
$212.73M
1W Leistung:
-0.35%
1M Leistung:
-2.86%
6M Leistung:
+0.59%
1J Leistung:
+23.42%
1-Tages-Spanne:
$315.81
$317.24
1-Wochen-Bereich:
$315.81
$321.80
52-Wochen-Spanne:
$221.26
$362.41
Penumbra Inc Stock (PEN) Company Profile
Firmenname
Penumbra Inc
Sektor
Branche
Telefon
(510) 995-2486
Adresse
ONE PENUMBRA PLACE, ALAMEDA, CA
Compare PEN vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PEN
Penumbra Inc
|
317.20 | 12.48B | 1.45B | 171.05M | 212.73M | 4.3459 |
ABT
Abbott Laboratories
|
88.41 | 153.99B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
307.80 | 118.00B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
79.34 | 101.86B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
45.29 | 67.32B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
87.36 | 50.30B | 6.30B | 1.07B | 1.09B | 1.8406 |
Penumbra Inc Stock (PEN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-18 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2025-12-11 | Hochstufung | Citigroup | Neutral → Buy |
| 2025-11-18 | Eingeleitet | Wells Fargo | Underweight |
| 2025-10-08 | Hochstufung | Needham | Hold → Buy |
| 2025-09-02 | Eingeleitet | Evercore ISI | Outperform |
| 2025-03-14 | Eingeleitet | BofA Securities | Buy |
| 2025-01-21 | Eingeleitet | UBS | Buy |
| 2024-12-17 | Eingeleitet | Oppenheimer | Outperform |
| 2024-12-11 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-09-18 | Eingeleitet | Stifel | Buy |
| 2024-09-03 | Eingeleitet | Leerink Partners | Outperform |
| 2024-07-31 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-07-31 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-02-23 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2023-09-06 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2023-07-19 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-03-29 | Herabstufung | Needham | Buy → Hold |
| 2023-01-30 | Eingeleitet | Piper Sandler | Overweight |
| 2022-11-04 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-10-12 | Eingeleitet | Jefferies | Buy |
| 2022-10-05 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-09-09 | Hochstufung | Needham | Hold → Buy |
| 2022-07-18 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-04-19 | Eingeleitet | Deutsche Bank | Buy |
| 2022-03-08 | Eingeleitet | Needham | Hold |
| 2021-09-16 | Eingeleitet | Truist | Buy |
| 2021-06-04 | Hochstufung | BTIG Research | Neutral → Buy |
| 2020-12-16 | Herabstufung | BTIG Research | Buy → Neutral |
| 2020-10-07 | Fortgesetzt | Canaccord Genuity | Buy |
| 2020-09-29 | Eingeleitet | BTIG Research | Buy |
| 2020-09-08 | Herabstufung | BofA Securities | Buy → Neutral |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2019-06-13 | Bestätigt | BofA/Merrill | Buy |
| 2019-05-30 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-05-21 | Eingeleitet | William Blair | Outperform |
| 2018-10-29 | Fortgesetzt | BofA/Merrill | Buy |
| 2018-10-08 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2018-02-21 | Eingeleitet | William Blair | Outperform |
| 2018-01-02 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2015-11-30 | Bestätigt | Canaccord Genuity | Buy |
| 2015-10-13 | Eingeleitet | Wells Fargo | Outperform |
Alle ansehen
Penumbra Inc Aktie (PEN) Neueste Nachrichten
Penumbra (NYSE:PEN) Medical Device Mid Caps Stay In Focus - Kalkine Media
Microcatheter Market Size to Reach USD 1.79 Billion by 2035 | SNS Insider - GlobeNewswire Inc.
Penumbra Receives CE Nod for THUNDERBOLT: Stock to Gain? - Yahoo Finance
Why Penumbra Lightning Flash is drawing attention in stroke care - AD HOC NEWS
Penumbra wins CE mark for Thunderbolt clot removal tech - MedTech Dive
Penumbra Inc (PEN) Valuation: PE, PB & Fair Value Analysis - TradingKey
Penumbra Inc (PEN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Penumbra (PEN) Proxy filing Summary - Quartr
Penumbra Inc (PEN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Penumbra Inc (PEN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Penumbra Inc (PEN) Institutional Confidence - TradingKey
Penumbra Inc (PEN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Penumbra Inc (PEN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Penumbra Inc (PEN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Ursa Fund Management, LLC's Penumbra Inc(PEN) Holding History - GuruFocus
Penumbra’s Thunderbolt approval poised to accelerate neuro thrombectomy innovation - Yahoo Finance
VIP Mid Cap Portfolio's Penumbra Inc(PEN) Holding History - GuruFocus
CE Mark Granted to Penumbra's CAVT Platform - dicardiology.com
Penumbra (PEN) Achieves CE Mark for Thunderbolt Technology - GuruFocus
Penumbra expands CAVT for stroke into Europe with Thunderbolt CE mark - NeuroNews International
Penumbra earns CE mark for Thunderbolt thrombectomy system - MassDevice
Penumbra’s Thunderbolt Computer-Assisted Vacuum Thrombectomy Earns CE Mark - Medical Product Outsourcing
Penumbra Inc Expands Cavt For Stroke To Europe With CE Mark For Thunderbolt - TradingView
Penumbra secures CE Mark for stroke treatment device in Europe - Investing.com
Penumbra secures CE Mark for stroke treatment device in Europe By Investing.com - Investing.com India
Penumbra Expands CAVT for Stroke to Europe with CE Mark for THUNDERBOLT - PR Newswire
Boston Scientific Eyes Neurovascular Growth With Penumbra Thunderbolt Clearance - Yahoo Finance UK
Penumbra CAVT Platform Receives FDA Clearance - dicardiology.com
FDA clears Penumbra’s Thunderbolt thrombectomy platform for stroke - Yahoo Finance
FDA OKs Penumbra’s Thunderbolt Computer-Assisted Vacuum Thrombectomy for Stroke - Medical Product Outsourcing
Penumbra, Inc. to Present at the Canaccord Genuity Growth Conference - GuruFocus
Penumbra's THUNDERBOLT Receives FDA ClearanceBringing Computer Assisted Vacuum Thrombectomy Technology to Stroke - The Malaysian Reserve
Penumbra wins FDA clearance for Thunderbolt computer-assisted vacuum thrombectomy for stroke - MassDevice
Penumbra (PEN) Receives FDA Clearance for Innovative Thrombectom - GuruFocus
Penumbra receives FDA clearance for stroke treatment device By Investing.com - Investing.com Australia
Penumbra receives FDA clearance for stroke treatment device - Investing.com
Computer-guided THUNDERBOLT device designed to speed stroke clot removal - Stock Titan
Penumbra, Inc. to Present at the 41st Annual J.P. Morgan Healthc - GuruFocus
(PEN) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Investor Outlook: Penumbra, Inc. (PEN) Boasts 13.36% Potential Upside Amid Strong Revenue Growth - DirectorsTalk Interviews
Total operating expenses of Penumbra, Inc. – XETR:0P8 - TradingView
Tangible book value per share of Penumbra, Inc. – XETR:0P8 - TradingView
Non-controlling/minority interest of Penumbra, Inc. – XETR:0P8 - TradingView
Penumbra, Inc. Cash Flow – XETR:0P8 - TradingView
Penumbra, Inc. Balance Sheet – XETR:0P8 - TradingView
PEN Technical Analysis & Stock Price Forecast - Intellectia AI
Why Is Penumbra (PEN) Down 1.2% Since Last Earnings Report? - Yahoo Finance
Here’s What Supports Penumbra’s (PEN) Revenue Growth and Margin Expansion - Insider Monkey
0P8 Stock Price and Chart — XETR:0P8 - TradingView
Grewal Harpreet, Penumbra director, sells $32,822 in stock - Investing.com
JP Morgan Upgrades Penumbra (PEN) - MSN
Finanzdaten der Penumbra Inc-Aktie (PEN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.93%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):